Butyrolactone I Derivatives from Aspergillus terreus Carrying an Unusual Sulfate Moiety.

Butyrolactone I Derivatives from Aspergillus terreus Carrying an Unusual Sulfate Moiety. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Butyrolactone I Derivatives from Aspergillus terreus Carrying an Unusual Sulfate Moiety. Abstract Text:

In our ongoing search for new bioactive metabolites from microbial resources, Aspergillus terreus (HKI0499) was examined by chemical metabolite profiling. Together with the known butyrolactone I ( 3), the unusual sulfate derivatives butyrolactone I 3-sulfate ( 1) and butyrolactone I 4''-sulfate ( 2) were discovered. The chemical structures were determined by NMR and MS data analyses. All compounds were tested on CDK1/cyclin B, CDK5/p25, DYRK1A, CK1, and GSK-3alpha/beta kinases; compounds 2 and 3 were also evaluated for their cytotoxic and antiproliferative activities. Butyrolactone I 3-sulfate ( 1) exhibited specific inhibitory activity against CDK1/cyclin B and CDK5/p25, yet 15-30-fold less than butyrolactone I ( 3). Likewise, butyrolactone I 3-sulfate ( 1) exhibited moderate cytotoxicity solely against HeLa cells (CC 50 = 80.7 microM).

Butyrolactone I Derivatives from Aspergillus terreus Carrying an Unusual Sulfate Moiety. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Butyrolactone I Derivatives from Aspergillus terreus Carrying an Unusual Sulfate Moiety. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of natural products

VOLUME: 71

Page Numbers: 689-92

Journal Abbreviation: J. Nat. Prod.

ISSN: 0163-3864

DAY: 14

MONTH: 02

YEAR: 2008

Butyrolactone I Derivatives from Aspergillus terreus Carrying an Unusual Sulfate Moiety. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7906882

Butyrolactone I Derivatives from Aspergillus terreus Carrying an Unusual Sulfate Moiety. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Butyrolactone I Derivatives from Aspergillus terreus Carrying an Unusual Sulfate Moiety. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Butyrolactone I Derivatives from Aspergillus terreus Carrying an Unusual Sulfate Moiety.

AFFILIATION: isabel.sattler@hki-jena.de.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Nat Prod

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Butyrolactone I Derivatives from Aspergillus terreus Carrying an Unusual Sulfate Moiety Related Publications

• Butyrolactone I Derivatives from Aspergillus terreus Carrying an Unusual Sulfate Moiety.
• Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications.
• Comparison of RRR-alpha- and all-rac-alpha-tocopherol uptake by permanent rat skeletal muscle myoblasts (L6 cells): effects of exogenous lipoprotein lipase.
• Connection piece for hearing device support hook.
• Decreasing asthmagens in hospitals.
• Dynamic effects on j-couplings across hydrogen bonds in proteins.
• Improving outcomes in pediatric procedural sedation.
• Inhibition of lung carcinoma cell growth by high density lipoprotein-associated alpha-tocopheryl-succinate.
• Lipoprotein-associated alpha-tocopheryl-succinate inhibits cell growth and induces apoptosis in human MCF-7 and HBL-100 breast cancer cells.
• New Abietane Diterpenoids from the Mangrove Avicennia marina.
• New report on decreasing asthmagens in hospitals.
• Our bodies and the legacy of "better living through chemistry.
• Pathogenesis and treatment of lipodystrophy: what clinicians need to know.
• Reliability of maximal voluntary muscle strength and power testing in older men.
• Results of alloarthroplasty of the hip joint.
• Site-specific variations of carbonyl chemical shift anisotropies in proteins.
• Structure and functional analysis of the MYND domain.
• Structure, derivatization, and antitumor activity of new griseusins from Nocardiopsis sp.
• Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).
• The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.
• [Demonstration of I/i- and Pr-antigens on lymphocytes by cold agglutinins (proceedings)]
• [Esophagus carcinoma in young adults.]
• [Experiences with a barbituric acid-free hypnotic combination.]
• [Not Available.]